Product Monograph

PATIENT INFORMATION

Important Safety Information

UBRELVY is indicated for the acute treatment of migraine, with or without aura, in adults.

UBRELVY MECHANISM OF ACTION^1*

Calcitonin gene-related peptide (CGRP) is a neuropeptide present in the peripheral and central nervous system. CGRP is released from sensory nerve endings during a migraine attack, particularly the nerve endings of sensory trigeminal ganglion neurons.^1*

UBRELVY is a small molecule, high affinity (K_i = 0.07nM) CGRP receptor antagonist (gepant).^1*

UBRELVY blocks the binding of CGRP to its receptor and antagonizes CGRP receptor function.^1*

UBRELVY may relieve migraine by halting the cascade of CGRP-induced neurogenic inflammation, blocking CGRP-induced neurogenic vasodilation, and/or inhibiting the central relay of pain signals from the trigeminal nerve to the caudal trigeminal nucleus.^1*

PHARMACOKINETICS*

UBRELVY is rapidly absorbed following oral administration with peak plasma concentrations observed around 1.5 hours post-dose.¹

The elimination half-life of ubrogepant is approximately 5-7 hours.¹

PHARMACOKINETICS*

UBRELVY is rapidly absorbed following oral administration with peak plasma concentrations observed around 1.5 hours post-dose.¹

The elimination half-life of ubrogepant is approximately 5-7 hours.¹

SAFETY INFORMATION

Click here for additional safety information and for a link to the Product Monograph discussing:

●Contraindications with concomitant use of strong CYP3A4 inhibitors.

●Relevant warnings and precautions regarding driving and operating machinery, hypersensitivity reactions, may reduce effectiveness of oral contraceptives, use in pregnant or breastfeeding women and dose selection in geriatric patients.

●Conditions of clinical use, adverse reactions, drug interactions and dosing instructions.

FOR MORE INFORMATION

For any questions related to UBRELVY, you can contact AbbVie Medical Information at 1-844-241-5011.

SAFETY INFORMATION

Click here for additional safety information and for a link to the Product Monograph discussing:

●Contraindications with concomitant use of strong CYP3A4 inhibitors.

●Conditions of clinical use, adverse reactions, drug interactions and dosing instructions.

FOR MORE INFORMATION

For any questions related to UBRELVY, you can contact AbbVie Medical Information at 1-844-241-5011.

SAFETY INFORMATION

Click here for additional safety information and for a link to the Product Monograph discussing:

●Contraindications with concomitant use of strong CYP3A4 inhibitors.

●Conditions of clinical use, adverse reactions, drug interactions and dosing instructions.

FOR MORE INFORMATION

For any questions related to UBRELVY, you can contact AbbVie Medical Information at
1-844-241-5011.

CGRP=calcitonin gene-related peptide.

* Clinical significance unknown. 

† Comparative clinical significance unknown.  

References:

1. UBRELVY (ubrogepant) Product Monograph. AbbVie Corporation.

2. Data on File, AbbVie Corporation.

3. “Summary Basis of Decision – Ubrelvy”. Health Canada. Updated March 30, 2023. https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailTwo.php?lang=en&linkID=SBD00631 (accessed April 19, 2023).

UBRELVY and its design are trademarks of Allergan Pharmaceuticals International Limited, an AbbVie company, used under license by AbbVie Corporation.

CA-UBR-260029A / JN26

UBRELVY and its design are trademarks of Allergan Pharmaceuticals International Limited, an AbbVie company, used under license by AbbVie Corporation.

CA-UBR-260029A / JN26

In vitro studies in coronary, meningeal and cerebral artery strips indicate that UBRELVY lacks vasoconstrictive effects in cranial and coronary arteries.^1*

* Clinical significance unknown. 

Reference:

1. UBRELVY (ubrogepant) Product Monograph. AbbVie Corporation.

In vitro studies in coronary, meningeal and cerebral artery strips indicate that UBRELVY lacks vasoconstrictive effects in cranial and coronary arteries.^1*

* Clinical significance unknown. 

Reference:

1. UBRELVY (ubrogepant) Product Monograph. AbbVie Corporation.

UBRELVY MECHANISM OF ACTION1*

UBRELVY MECHANISM OF ACTION1*

PHARMACOKINETICS*

PHARMACOKINETICS*

SAFETY INFORMATION

FOR MORE INFORMATION

SAFETY INFORMATION

FOR MORE INFORMATION

SAFETY INFORMATION

FOR MORE INFORMATION

References:

In vitro studies in coronary, meningeal and cerebral artery strips indicate that UBRELVY lacks vasoconstrictive effects in cranial and coronary arteries.1*

Reference:

In vitro studies in coronary, meningeal and cerebral artery strips indicate that UBRELVY lacks vasoconstrictive effects in cranial and coronary arteries.1*

Reference:

UBRELVY MECHANISM OF ACTION^1*

UBRELVY MECHANISM OF ACTION^1*

In vitro studies in coronary, meningeal and cerebral artery strips indicate that UBRELVY lacks vasoconstrictive effects in cranial and coronary arteries.^1*

In vitro studies in coronary, meningeal and cerebral artery strips indicate that UBRELVY lacks vasoconstrictive effects in cranial and coronary arteries.^1*